Literature DB >> 2076715

Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.

H Spahn1, H Knauf, E Mutschler.   

Abstract

The pharmacokinetics of 20 mg torasemide i.v. has been studied in 7 healthy controls and 9 patients with varying degrees of renal impairment. Torasemide had a t1/2 of about 4h which was independent of kidney function, as the nonrenal clearance of torasemide was 3-times greater than its renal clearance. The active metabolite M 1 and the main metabolite M 5 were accumulated in chronic renal failure. In contrast to liver function, therefore, kidney failure does not have an important effect on the pharmacokinetics of torasemide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076715     DOI: 10.1007/BF00315407

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency.

Authors:  L Dodion; J L Willems
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect.

Authors:  M Lesne; F Clerckx-Braun; P Duhoux; C van Ypersele de Strihou
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-08

4.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

5.  Massive propranolol metabolite retention during maintenance hemodialysis.

Authors:  W J Stone; T Walle
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

6.  Pharmacokinetics and metabolism of torasemide in man.

Authors:  G Neugebauer; E Besenfelder; E von Möllendorff
Journal:  Arzneimittelforschung       Date:  1988-01

7.  Comparison of efficacy and tolerance of different oral doses of torasemide and furosemide in patients with advanced chronic renal failure.

Authors:  J Kult; W Häcker; M Glocke
Journal:  Arzneimittelforschung       Date:  1988-01

8.  Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver.

Authors:  G Brunner; K von Bergmann; W Häcker; E von Möllendorff
Journal:  Arzneimittelforschung       Date:  1988-01

9.  Torasemide for diuretic treatment of advanced chronic renal failure.

Authors:  W Clasen; T Khartabil; S Imm; J Kindler
Journal:  Arzneimittelforschung       Date:  1988-01

10.  Dose-dependent salidiuretic efficacy of torasemide in comparison to furosemide and placebo in advanced renal failure.

Authors:  G Mourad; W Haecker; C Mion
Journal:  Arzneimittelforschung       Date:  1988-01
  10 in total
  9 in total

1.  Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics and pharmacodynamics of torasemide.

Authors:  H Knauf; E Mutschler
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 4.  The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.

Authors:  H Knauf; H Spahn; E Mutschler
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Torasemide. A review of its pharmacological properties and therapeutic potential.

Authors:  H A Friedel; M M Buckley
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 6.  Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

8.  Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis.

Authors:  H Knauf; E Mutschler; H Velazquez; G Giebisch
Journal:  Eur J Clin Pharmacol       Date:  2009-02-20       Impact factor: 2.953

9.  Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.

Authors:  Gustavo F Agne; Seung Woo Jung; Anne A Wooldridge; Susan H Duran; William Ravis; Ramiro Toribio
Journal:  J Vet Intern Med       Date:  2018-05-17       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.